Piotr P Buszman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11905712/publications.pdf

Version: 2024-02-01

840776 677142 22 532 11 22 citations h-index g-index papers 22 22 22 965 times ranked citing authors all docs docs citations

#	Article	IF	CITATIONS
1	Neointimal hyperplasia of ultra-thin stents with microcrystalline sirolimus or durable polymer everolimus-eluting stents: 6- and 24-month results of the DESSOLVE III OCT study. EuroIntervention, 2021, 16, 1187-1194.	3.2	2
2	Microcrystalline paclitaxel-coated balloon for revascularization of femoropopliteal artery disease: Three-year outcomes of the randomized BIOPAC trial. Vascular Medicine, 2021, 26, 401-408.	1.5	6
3	Long term outcomes in diabetic patients treated with atherectomy for peripheral artery disease. Cardiology Journal, 2020, 27, 600-607.	1.2	3
4	Clinical Randomized Trial Evaluating Novel, Microcrystalline, and Biocompatible Polymer Paclitaxel-Coated Balloon forÂthe Treatment of Femoropopliteal Occlusive Disease. JACC: Cardiovascular Interventions, 2018, 11, 2436-2438.	2.9	8
5	Long-Term Outcomes After Percutaneous Lower Extremity Arterial Interventions With Atherectomy vs. Balloon Angioplasty ― Propensity Score-Matched Registry ―. Circulation Journal, 2017, 81, 376-382.	1.6	4
6	A Nuclear Magnetic Resonance Spectroscopy as a Method for Evaluation of In Vivo Poly- <scp>I</scp> -Lactide Biodegradation Kinetics From Stent-Polymer Matrices. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 93-99.	2.0	7
7	Left Main Stenting in Comparison WithÂSurgical Revascularization. JACC: Cardiovascular Interventions, 2016, 9, 318-327.	2.9	129
8	Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. EuroIntervention, 2016, 12, e623-e631.	3.2	17
9	Comparable vascular response of a new generation sirolimus eluting stents when compared to fluoropolymer everolimus eluting stents in the porcine coronary restenosis model. Cardiology Journal, 2016, 23, 657-666.	1.2	12
10	Stenting and Adjunctive Delivery of Paclitaxel Via Balloon Coating Versus Durable Polymeric Matrix for De Novo Coronary Lesions: Clinical and Angiographic Results from the Prospective Randomized Trial. Journal of Interventional Cardiology, 2015, 28, 348-357.	1.2	12
11	Experimental evaluation of pharmacokinetic profile and biological effect of a novel paclitaxel microcrystalline balloon coating in the iliofemoral territory of swine. Catheterization and Cardiovascular Interventions, 2014, 83, 325-333.	1.7	19
12	Comparison of Stenting and Surgical Revascularization Strategy in Non-ST Elevation Acute Coronary Syndromes and Complex Coronary Artery Disease (from the Milestone Registry). American Journal of Cardiology, 2014, 114, 979-987.	1.6	16
13	Tissue Uptake, Distribution, and Healing Response After Delivery of Paclitaxel via Second-Generation lopromide-Based Balloon Coating. JACC: Cardiovascular Interventions, 2013, 6, 883-890.	2.9	40
14	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention for Ostial/Mid-Shaft Lesions Versus Distal Bifurcation Lesions in Unprotected LeftÂMain Coronary Artery. JACC: Cardiovascular Interventions, 2013, 6, 1242-1249.	2.9	75
15	Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy: Insights from a multicenter, propensity scoreâ€matched registry. Catheterization and Cardiovascular Interventions, 2013, 82, E155-62.	1.7	6
16	Stent healing response following delivery of paclitaxel via durable polymeric matrix versus iopromide-based balloon coating in the familial hypercholesterolaemic swine model of coronary injury. EuroIntervention, 2013, 9, 510-516.	3.2	7
17	Controlled Reperfusion with Intravenous Bivalirudin and Intracoronary Abciximab Combination Therapy in the Porcine Myocardial Infarction Model. Thrombosis Research, 2012, 130, 265-272.	1.7	15
18	Effects of intracoronary delivery of allogenic bone marrow-derived stem cells expressing heme oxygenase-1 on myocardial reperfusion injury. Thrombosis and Haemostasis, 2012, 108, 464-475.	3.4	21

#	Article	IF	CITATIONS
19	Vascular response and mechanical integrity of the new biodegradable polymer coated sirolimus-eluting PROLIM stent implanted in porcine coronary arteries. Kardiologia Polska, 2012, 70, 703-11.	0.6	4
20	Effects of local intracoronary paclitaxel delivery using the Remedy transport catheter on neointimal hyperplasia after stent implantation in a porcine model. Cardiovascular Revascularization Medicine, 2011, 12, 82-89.	0.8	2
21	Early and Long-Term Results of Unprotected Left Main Coronary Artery Stenting. Journal of the American College of Cardiology, 2009, 54, 1500-1511.	2.8	118
22	Early and long-term outcomes after surgical and percutaneous myocardial revascularization in patients with non-ST-elevation acute coronary syndromes and unprotected left main disease. Journal of Invasive Cardiology, 2009, 21, 564-9.	0.4	9